One chew that covers three months of flea and tick protection sounds like a dream — and for most dogs it genuinely works that way. But Bravecto carries a boxed warning that matters, a dosing structure that trips up even careful owners, and a brand-new injectable version that changes the math entirely for dogs who refuse pills. This guide answers the questions your vet doesn’t always have time to.
The questions dog owners actually search — answered without the runaround. Each answer below is sourced from FDA labeling, peer-reviewed studies, or Merck Animal Health product documentation.
The evidence is genuinely strong. In a multi-site, randomized field study comparing Bravecto chews against Frontline (fipronil), Bravecto achieved 99.2%–99.9% flea-control efficacy across the full 12-week period, while fipronil’s performance declined substantially between treatments. The FDA required Merck to demonstrate efficacy through controlled U.S. field studies before approval, and those studies were conducted in real homes with naturally infested dogs — not laboratory-only conditions. The 12-week duration isn’t a marketing estimate; it’s the period for which the manufacturer established efficacy through regulated studies. For the lone star tick (Amblyomma americanum), protection is established for 8 weeks, not 12 — which matters if you live in the southeastern or south-central U.S. where that species is common.
Fluralaner, Bravecto’s active ingredient, belongs to the isoxazoline drug class — the same class as NexGard, Credelio, and Simparica. Isoxazolines carry an FDA-mandated label warning about a known, if rare, risk of neurological adverse reactions, including tremors, unsteady gait (ataxia), and seizures. Because the drug requires a risk assessment for each individual dog — particularly those with a history of seizures or neurological disease — the FDA requires a veterinary prescription. The prescription requirement exists specifically to give your vet the chance to evaluate whether Bravecto is appropriate for your dog before it’s dispensed. This isn’t bureaucratic caution; it’s the correct use of a medication that can trigger neurological events in susceptible animals.
Not automatically, but it requires a careful conversation with your veterinarian. The FDA label for Bravecto Chews states directly: “Use with caution in dogs with a history of seizures or neurologic disorders.” The label also notes that seizures have been reported in dogs receiving isoxazoline drugs even in dogs without a prior seizure history. The clinical reality is that the absolute risk is low — but it is not zero, and in a dog already prone to seizures, even a small additional trigger carries higher stakes. Your vet may choose an alternative ectoparasiticide class entirely, such as a permethrin-based topical or a collar-based prevention that doesn’t involve systemic isoxazolines. Do not assume your vet already knows about your dog’s seizure history — confirm it is in the record before any isoxazoline product is prescribed.
No. This is one of the most common and consequential misunderstandings about Bravecto. Fluralaner kills fleas and ticks — it has no efficacy against heartworm larvae, heartworm adults, roundworms, hookworms, or any internal parasite. Dogs on Bravecto still need a dedicated monthly heartworm preventive, ideally one that also covers intestinal parasites. Some owners switch to Bravecto from a combination monthly product and unknowingly drop their heartworm coverage in the process. If you’re making any change to your parasite prevention routine, confirm with your vet that heartworm prevention is explicitly part of the new plan — it should never be the casualty of a product switch.
Bravecto Quantum is an injectable, extended-release formulation of fluralaner that the FDA approved in July 2025. A veterinarian administers a single subcutaneous injection and the dog is protected against fleas and four tick species for a full 12 months. In March 2026, the FDA expanded Quantum’s label to also cover Asian longhorned ticks and Gulf Coast ticks for 12 months. The drug in the injection is the same fluralaner; the difference is the delivery system — a controlled-release depot that slowly releases the active ingredient over the year. Quantum is a meaningful option for dogs that refuse chews, for households where someone routinely forgets the 12-week dose, and for boarding facilities that require documentation of year-round coverage. It requires a vet visit to administer, which adds a clinic fee, but eliminates eleven monthly or four quarterly dosing events.
The Bravecto 12-Week Chew and Bravecto Topical are labeled for dogs and puppies 6 months of age and older, weighing at least 4.4 pounds. The Bravecto 1-Month Chew is also labeled for puppies 6 months and older. There is no approved Bravecto formulation for puppies under 6 months — using it younger is extra-label use and requires your vet’s explicit judgment. The age minimum exists because fluralaner’s safety profile was established in studies beginning at 6 months; the drug hasn’t been evaluated at sufficient scale in younger animals to support a younger label. If you have a puppy under 6 months with a flea or tick problem, ask your vet specifically about puppy-appropriate alternatives. Several monthly flea preventives are approved down to 8 weeks of age.
According to the FDA label, Bravecto Chews have been tested in breeding, pregnant, and lactating dogs at doses up to 168 mg/kg — roughly three times the recommended dose — with no clinically significant adverse effects on reproductive performance, litter size, or pup health. The label states it “can be used” in breeding, pregnant, and lactating dogs. However, the FDA label for the 1-Month Chew includes the separate statement that “safety has not been evaluated in breeding, pregnant and lactating dogs” for that specific formulation. The distinction matters: safety data exists for the standard 12-Week Chew, but is not established for the 1-Month formulation. Always confirm which specific Bravecto product your vet is prescribing and verify what the label says for that exact formulation before use in a breeding or pregnant dog.
For the chewable tablet, water exposure has no impact on efficacy — the drug is systemic, absorbed through the gut, and circulates in the bloodstream. Bathing or swimming does not wash off the active ingredient. For the topical solution, Merck’s prescribing directions recommend waiting 72 hours after application before immersing the dog in water. Studies showed that water immersion before that 72-hour window can reduce the drug’s absorption through the skin, which could lower the blood concentration below the level needed for full protection. If your dog is a regular swimmer or gets bathed frequently, the chewable tablet is the more reliable option — the topical requires that initial absorption window that water disrupts. After the 72 hours have passed, the topical’s protection is not affected by subsequent water exposure.
Understanding how fluralaner actually kills parasites explains why the 12-week duration is real, why it works fast, and why the neurological warning on the label exists — even though serious events are rare in healthy dogs.
When your dog swallows a Bravecto chew, the active ingredient fluralaner is absorbed through the digestive tract and distributed throughout the bloodstream. Fluralaner is not a contact-kill product — it doesn’t coat the skin or fur. Instead, it circulates in the blood, which means that when a flea or tick bites your dog and takes a blood meal, it ingests the drug. The parasite’s nervous system then overloads and it dies. This is why Bravecto requires the parasite to bite your dog first — it is a treatment-after-bite system, not a repellent. For Lyme disease prevention, this matters: a tick must be attached long enough to bite, but Bravecto kills the tick so rapidly after biting that transmission risk is dramatically reduced.
Fluralaner works by blocking ligand-gated chloride ion channels — specifically the GABA and glutamate receptors — in the nervous system of insects and arachnids. This blockade causes uncontrolled nerve firing, paralysis, and death in the parasite. The selectivity that makes isoxazolines relatively safe for mammals is that invertebrate GABA receptors differ structurally from mammalian ones — the drug preferentially binds the invertebrate version. However, this selectivity is not absolute. Mammalian GABA receptors can be affected at sufficient concentrations, which is the pharmacological basis for the neurological warning on the label. In the vast majority of dogs, blood levels stay well within the safe range. In dogs with compromised blood-brain barrier function or pre-existing neurological vulnerability, the margin may be narrower.
Fluralaner is highly lipophilic — it bonds strongly to fat-like proteins in the blood and tissues. This protein-binding characteristic slows the drug’s elimination dramatically, keeping circulating concentrations above the parasitically effective threshold for approximately 12 weeks after a single dose. This isn’t a slow-release coating or capsule technology; it’s inherent to how the molecule behaves chemically once absorbed. Studies confirm that flea-kill efficacy remains above 99% at week 12 after dosing. What this also means: the drug doesn’t leave your dog’s system quickly. If a side effect does occur, it can persist longer than with a medication that clears within 24 hours. That’s a reason the seizure caution exists — not to discourage use, but to ensure owners know they should report neurological symptoms promptly and that supportive care may be needed for longer than expected.
Bravecto begins killing fleas within approximately 2 hours of oral administration, reaching sustained lethal concentrations for fleas rapidly. For ticks, the onset is somewhat slower — studies show tick mortality beginning within 12 hours of the dose. The FDA confirmed onset of effectiveness against black-legged ticks, American dog ticks, and brown dog ticks within this 12-hour window in controlled studies. Practical implication: if your dog is currently visibly infested, Bravecto will start reducing the live flea and tick burden quickly — but you may still see dying or dead parasites on the dog for a day or two as the dose takes full effect. Seeing a flea or tick shortly after the first dose is not automatically a sign of treatment failure; it may simply be a parasite in its final hours.
Dosing is weight-based with no flexibility — give the chew that matches your dog’s actual current weight, not an estimate. Dogs who fall between weight bands receive the higher bracket. Always weigh your dog before each dose, especially puppies who are still growing. Bravecto must be given with a full meal; bioavailability is significantly reduced when given to a fasted dog.
| Dog Weight | Chew Strength (12-Wk) | Chew Strength (1-Mo) | Fluralaner Dose | Lone Star Tick? | Next Dose Due |
|---|---|---|---|---|---|
| 4.4–9.9 lbs | 112.5 mg | 45 mg | Min 25 mg/kg | 8 weeks only | 12 weeks (or 8 wks if lone star risk) |
| 9.9–22 lbs | 250 mg | 100 mg | Min 25 mg/kg | 8 weeks only | 12 weeks (or 8 wks if lone star risk) |
| 22–44 lbs | 500 mg | 200 mg | Min 25 mg/kg | 8 weeks only | 12 weeks (or 8 wks if lone star risk) |
| 44–88 lbs | 1,000 mg | 400 mg | Min 25 mg/kg | 8 weeks only | 12 weeks (or 8 wks if lone star risk) |
| 88–123 lbs | 1,400 mg | 560 mg | Min 25 mg/kg | 8 weeks only | 12 weeks (or 8 wks if lone star risk) |
| Over 123 lbs | Combination of two chews required — ask your vet | Min 25 mg/kg | 8 weeks only | 12 weeks (or 8 wks if lone star risk) | |
Bravecto Chews provide 12 weeks of protection against four tick species. But for the lone star tick (Amblyomma americanum) — the most common tick across the southeastern and south-central United States — the FDA-confirmed protection period is only 8 weeks per dose, not 12. If you live in Texas, Florida, Georgia, the Carolinas, Virginia, or anywhere the lone star tick is active, your dog needs a Bravecto dose every 8 weeks, not every 12 weeks. Giving the chew every 12 weeks on a “standard schedule” in lone star tick territory leaves a four-week window of reduced protection against that specific species. Ask your vet whether you live in lone star tick country — the Companion Animal Parasite Council (capcvet.org) maintains a current regional tick prevalence map.
Bravecto now comes in four distinct formulations in the U.S., each with different durations, delivery methods, and clinical use cases. Knowing which product your vet prescribed matters — the labels differ in meaningful ways.
The original and most widely dispensed formulation — a pork-flavored chewable tablet given orally every 12 weeks (or every 8 weeks for lone star tick coverage). Available in five weight-based strengths from 112.5 mg to 1,400 mg. Most dogs accept the chew as a treat; for dogs that don’t, the tablet can be broken and placed in food. Must be given with a full meal. This is the formulation with the most extensive real-world safety data, having been on the U.S. market since 2014. It’s the one most veterinarians are referring to when they simply say “Bravecto.” Labeled safe for breeding, pregnant, and lactating dogs when used as directed.
The same active ingredient (fluralaner) at a lower per-dose concentration, formulated for monthly rather than quarterly dosing. Five weight-based strengths (45 mg, 100 mg, 200 mg, 400 mg, 560 mg). The 1-Month Chew appeals to owners who want the dosing rhythm of a monthly product but prefer Bravecto over competing monthly isoxazolines. One important label distinction from the 12-Week Chew: the safety of the 1-Month Chew has not been evaluated in breeding, pregnant, and lactating dogs. This is not a minor footnote — if your dog is pregnant or nursing, discuss this gap with your vet and consider using the 12-Week Chew instead, where the pregnancy safety data does exist.
A spot-on liquid applied directly to the skin at the base of the neck, absorbed transdermally and distributed systemically. Same 12-week protection duration as the chewable. Five weight-appropriate tube strengths (112.5 mg to 1,400 mg fluralaner). The topical is prescribed when a dog consistently refuses or regurgitates the oral chew, or when an owner finds topical application easier to manage. The 72-hour water restriction after application is not optional — bathing or swimming before the drug has fully absorbed through the skin can reduce blood concentrations below effective levels. After the 72-hour window, subsequent water exposure doesn’t affect the product’s efficacy. Not recommended for dogs with known skin conditions at the application site.
A veterinarian-administered subcutaneous injection that provides 12 months of flea and tick protection from a single dose. FDA-approved in July 2025 for U.S. use, with an expanded label for Asian longhorned ticks and Gulf Coast ticks added in March 2026. The drug concentration is 150 mg/mL fluralaner; dosing is 15 mg/kg body weight. In a U.S. field study involving 225 dogs, 0.9% experienced seizures — a rate the FDA and manufacturer describe as consistent with background seizure rates in the general dog population. Quantum is the most significant change to flea and tick prevention in years — it eliminates the compliance problem entirely. One clinic visit replaces 4 quarterly chews or 12 monthly chews. The trade-off: it’s more expensive per year than the chew, requires a vet appointment for administration, and if an adverse reaction occurs the drug cannot be reversed quickly.
Most dogs tolerate Bravecto without any observable side effect. But “most” isn’t “all,” and knowing what to watch for — and when to call your vet versus when to wait — is the information that saves you panic or prevents a serious situation from going unaddressed.
The most frequently reported adverse events from post-market surveillance, in decreasing order per the FDA label, are: vomiting, lethargy, diarrhea (with or without blood), reduced appetite, and flatulence. These are primarily gastrointestinal reactions and typically appear within the first few hours after dosing — most resolve without treatment within 24 hours. Giving the chew with a full meal is the most effective way to reduce GI side effects — the manufacturer’s prescribing directions specifically require food co-administration for this reason. If vomiting occurs within the first hour of dosing, contact your vet — the dog may not have absorbed a full dose, and a replacement may be appropriate.
The FDA issued a safety alert for the entire isoxazoline class — which includes Bravecto, NexGard, Simparica, and Credelio — specifically because neurological adverse events have been reported post-market: muscle tremors, ataxia (unsteady or stumbling gait), and seizures. These events have occurred in dogs with and without a prior history of neurological problems. The FDA requires this warning on all isoxazoline labels. The absolute incidence of serious neurological events with Bravecto is low — but low is not zero. If your dog shows any of the following within days of a dose, call your vet the same day:
- Muscle twitching, trembling, or shaking that is new or unusual for your dog
- Stumbling, loss of coordination, or falling
- A seizure — any involuntary muscle jerking or loss of consciousness
- Sudden behavioral changes such as extreme agitation or unresponsiveness
Dogs with the MDR1 (ABCB1) gene mutation — most commonly Collies, Shetland Sheepdogs, Australian Shepherds, Border Collies, and related herding breeds — have a reduced ability to pump certain drugs out of the brain, leading to higher brain concentrations of some medications. Ivermectin toxicity in Collies is the most famous example of this. Merck has specifically tested fluralaner in MDR1-affected dogs and did not observe adverse effects attributable to the mutation. The official position from Merck Animal Health and PetMD is that dogs with the MDR1 mutation are not considered at increased risk for Bravecto adverse effects. However, if your dog is a herding breed with known MDR1 positive status and you have concerns, discuss this explicitly with your vet — genetic testing for MDR1 status is available and inexpensive if the status is unknown.
Beyond GI and neurological events, post-approval adverse drug experience reporting to the FDA has included: pruritis (itching), polydipsia (increased thirst), allergic reactions including hives, skin swelling, and erythema, dermatitis, and — in rare cases — anaphylactic-type reactions. One laboratory study noted facial swelling (edema of the upper lips) in a single dog within one hour of dosing, which resolved without treatment by the next morning. The FDA notes that not all adverse events are reported to its Center for Veterinary Medicine, and that these reports don’t establish causation — some events that occur in the timeframe after dosing may be coincidental. If you believe your dog has had an adverse reaction to Bravecto, report it to the FDA at 1-888-FDA-VETS and to Merck Animal Health at 1-800-224-5318. Your report contributes to the surveillance system that identifies rare safety signals.
Bravecto requires a prescription, which means the price varies widely based on where you fill it. Vet clinic pharmacies, licensed online pet pharmacies, and discount retailers can differ by 30–65% for the identical product — and your vet’s prescription is transferable to any licensed pharmacy.
Per-dose pricing for the Bravecto 12-Week Chew varies by where you fill the prescription. At a veterinary clinic dispensary, expect $50–$80 per dose regardless of dog size (fixed pricing is common). At licensed online pet pharmacies such as Chewy’s pharmacy, 1800PetMeds, or PetMeds, per-dose prices range from roughly $40–$65. Discount-oriented online retailers report prices as low as $38–$42 per dose for smaller dogs, with larger sizes proportionally higher. On an annualized basis — four doses per year — the full-year cost at clinic pricing runs approximately $200–$320, while online purchasing brings that to $160–$260. Merck Animal Health runs a rebate program offering up to $25 back when purchasing four doses — effectively reducing per-dose cost by $6.25, on top of any retailer discount. The rebate is claimable online at the manufacturer’s website and requires proof of purchase.
Bravecto Quantum pricing is set by individual veterinary clinics and varies by region. Based on reported invoices, the drug itself is priced at $149–$219 per injection depending on veterinary market and dog size. This does not include the clinic’s administration and exam fees, which typically add $45–$75 for a wellness exam and $8–$15 for prescription handling or biohazard fees. An all-in Quantum visit therefore runs approximately $200–$310. Compared to the chewable tablet’s annual cost of $160–$320, Quantum may cost about the same or slightly more per year at most clinics — while eliminating all at-home dosing events. If you currently miss or delay any of the four annual chew doses, the real cost comparison shifts in Quantum’s favor — missed doses mean unprotected periods that the injection eliminates entirely.
- Fill the prescription online, not at the clinic. Your vet’s prescription is transferable — request a written or faxed copy and fill it at a licensed online pharmacy. Savings of 30–50% over clinic pricing are typical. Chewy’s pharmacy, 1800PetMeds, and PetMeds are the most widely used and accept faxed prescriptions.
- Apply for the manufacturer rebate every year. Merck offers a $25 rebate when you purchase four doses in a single transaction, available at us.bravecto.com. Set a calendar reminder — the rebate requires a registration within a set window after purchase.
- Ask your vet’s office about price matching. Many veterinary clinics will match the price of a licensed online pharmacy to retain your business and convenience — the conversation takes one minute and the answer is frequently yes.
- Check GoodRx Companion. GoodRx has expanded its discount platform to include pet medications at participating pharmacies. Bravecto has appeared as low as $28.99 on GoodRx for some formulations with a coupon at certain locations.
- Bundle with a wellness plan if your clinic offers one. Some veterinary clinics include discounted flea/tick prevention as part of an annual wellness package — the discount per medication often exceeds what you’d save buying individually online.
All three are isoxazoline-class flea and tick preventives requiring a prescription. The differences lie in duration, tick species coverage, and who they are best suited for. None of them cover heartworm.
| Product | Active Ingredient | Duration | Tick Species (Full Duration) | Lone Star Tick | Min Age | Heartworm? |
|---|---|---|---|---|---|---|
| Bravecto Chews | Fluralaner | 12 weeks | Black-legged, American dog, brown dog, Asian longhorned | 8 weeks only | 6 months | No |
| NexGard | Afoxolaner | 4 weeks | Black-legged, American dog, brown dog, lone star | 4 weeks (full) | 8 weeks | No |
| Simparica | Sarolaner | 4 weeks | Black-legged, American dog, brown dog, lone star, Gulf Coast | 4 weeks (full) | 6 months | No |
| Bravecto Quantum | Fluralaner | 12 months | Black-legged, American dog, brown dog, Asian longhorned, Gulf Coast | 8 months only | 6 months | No |
- Bravecto 12-Week Chew: Ideal if you want fewer dosing events per year, your dog eats chews readily, and you’re not in heavy lone star tick territory — or you’re prepared to dose every 8 weeks if you are.
- NexGard or Simparica (monthly): Better if you live in the southeastern U.S. where lone star ticks are prevalent, since monthly dosing gives complete lone star coverage without the 8-week gap. Also the right choice if you want to minimize how much drug stays in your dog’s system at any one time — monthly formulas clear faster.
- Bravecto Quantum (injectable): The choice for dogs that routinely avoid chews, for owners who travel frequently or have complex schedules where the 12-week dose regularly gets forgotten, or for boarding situations requiring documented year-round coverage with a vet record.
- None of the above: If your dog has a personal or family history of seizures or documented neurological disease, your vet should discuss alternatives outside the isoxazoline class — such as Seresto collar (imidacloprid + flumethrin) or Vectra 3D (dinotefuran + pyriproxyfen + permethrin), neither of which are isoxazolines.
Vomiting is the most commonly reported side effect and most often occurs within the first hour or two of dosing. If vomiting happens within the first 30–60 minutes, call your vet’s office — the dog may not have absorbed a sufficient dose, and a replacement may be recommended. If vomiting begins after the first hour, the drug has likely been absorbed and your vet may advise monitoring at home. Offer small amounts of water and watch for improvement. If vomiting continues beyond 6–8 hours, is projectile or forceful, or your dog shows additional symptoms such as trembling or unusual lethargy, call your vet the same day. Giving Bravecto with a larger meal — not just a treat — significantly reduces the risk of vomiting at the next dose. The manufacturer’s data show that co-administration with food meaningfully improves both tolerability and drug absorption.
Give the dose as soon as you realize it’s overdue and reset your schedule from that day. The honest truth: if significant time has passed since the dose was due, your dog may have had a period of reduced or no flea and tick protection — the drug concentration falls below effective levels at some point after 12 weeks. If your dog was exposed to ticks during the gap, a tick check and potentially a tick-borne disease screening at your next vet visit is reasonable, especially if you live in a Lyme-endemic area. If missed doses are a recurring problem for your household, that’s the single strongest argument for discussing Bravecto Quantum (the injectable) with your vet — one clinic visit eliminates the annual compliance problem entirely. A dose that isn’t given protects no one, regardless of how effective it would have been.
For the chewable tablet: yes, absolutely. The drug is systemic — it lives in the bloodstream, not on the coat or skin surface — so daily swimming, bathing, or any water exposure has zero effect on the oral chew’s efficacy. This is one of the genuine advantages of an oral formulation over older collar-based or topical products. For the topical spot-on Bravecto: daily swimmers are not ideal candidates. The 72-hour post-application window before water exposure isn’t negotiable — and for a dog that swims first thing every morning, consistently honoring that window is impractical. For frequent-swimmer dogs, discuss the chewable formulation with your vet rather than the topical.
First: the prescription requirement means you need a vet relationship. If cost is the barrier there, check whether your county humane society or local SPCA runs low-cost wellness clinics — many provide prescription-writing as part of a reduced-fee exam. Second, look at transferring any existing prescription to an online pharmacy; the price difference from a clinic dispensary to a licensed online retailer can be 40–50% for the same product. Third, ask your vet about alternatives — not every dog needs the most expensive option. Generic pet-market topicals with proven efficacy are available without a prescription in some cases, and your vet may know of options appropriate for your dog’s risk level. For flea control specifically, untreated infestations become exponentially more expensive and difficult to resolve — the cost of a professional exterminator and retreating your home typically exceeds a year of Bravecto. Prevention is the more economical path when weighed across the full scenario.
This concern circulates persistently on social media, and it deserves a direct, honest answer. Bravecto does carry a real FDA warning about neurological events — that warning is not marketing spin, it reflects actual post-market reports. But “adverse events were reported” is not the same as “the drug is unsafe.” The FDA reviewed all post-market safety data and chose to require a class label warning rather than withdraw the products — because the benefit-to-risk profile, for the population of dogs overall, remains favorable. Individual stories of adverse outcomes are real, and they should be taken seriously — but they should be evaluated in proportion to the tens of millions of doses dispensed. The most appropriate response to this concern is not to stop medication without a plan, but to tell your vet you have concerns, describe your dog’s specific history (especially any prior neurological events), and make an informed decision together. Stopping parasite prevention cold creates its own real health risks — including Lyme disease, Rocky Mountain spotted fever, anaplasmosis, and flea allergy dermatitis — that should be weighed against the low but documented risk of the drug.
Call your emergency vet or animal emergency clinic immediately — do not wait for the episode to resolve on its own before making the call. Tell them: the name of the medication (Bravecto, fluralaner), the dose given, the time it was administered, and exactly what the seizure looked like. After your dog is stable, report the adverse event to the FDA’s Center for Veterinary Medicine at 1-888-FDA-VETS or at fda.gov/safety/medwatch — your report contributes to the post-market surveillance that protects other dogs. Also report directly to Merck Animal Health at 1-800-224-5318. Because fluralaner has a long half-life, neurological symptoms from an isoxazoline reaction may last longer than a seizure from a different cause — your vet needs to know this is a medication-related event, not an idiopathic episode, so supportive care is appropriately continued. Your dog should not receive another isoxazoline-class product, and your vet should document the event in the medical record.
This guide is for general educational purposes and does not constitute veterinary medical advice. Bravecto is a prescription medication available only through a licensed veterinarian. Always consult your veterinarian before starting, changing, or stopping any medication for your pet. Drug information reflects publicly available FDA labeling and Merck Animal Health product documentation current as of the date of publication; drug labels may be updated — confirm current indications with your vet or at DailyMed (dailymed.nlm.nih.gov). Adverse event reporting: FDA Center for Veterinary Medicine, 1-888-FDA-VETS. This content is entirely original.